KQED’s Joshua Johnson talks with Dr. Andrew Zolopa, director of the Positive Care Clinic at Stanford about the benefits — and risks — of a drug that can help prevent people from acquiring HIV.

Peninsula-based drugmaker Gilead Sciences received permission from the FDA on Monday to sell its landmark daily pill, Truvada, to HIV-negative people as a way of protecting them from getting infected. Some researchers call it a step toward eradicating AIDS, while others fear it may be a step back from years of encouraging safer sex habits.

Read more at: www.kqed.org


Lisa Aliferis

Lisa Aliferis is the founding editor of KQED's State of Health blog. Since 2011, she's been writing stories and editing them for the site. Before taking up blogging, she toiled for many years producing health stories for television, including Dateline NBC and San Francisco's CBS affiliate, KPIX-TV. She also wrote up a handy guide to the Affordable Care Act, especially for Californians. You can follow her on Twitter: @laliferis

Sponsored by

Become a KQED sponsor